LY-272015 is a β-carboline derivative drug developed by Eli Lilly, which acts as a potent and selective antagonist at the serotonin 5-HT2B receptor. It has anti-hypertensive effects in animal models, and is also used in research into the other functions of the 5-HT2B receptor.
See also Substituted β-carboline LY-266097 Fenharmane 1-(2,4,5-Trimethoxyphenyl)-6-chlorotryptoline
References